Abbott Profit Tops Estimates as Humira Drug Sales Climb
This article is for subscribers only.
Abbott Laboratories, in the process of splitting into two companies, reported second-quarter earnings that beat analysts’ estimates as sales increased for the company’s top-selling drug, the arthritis medicine Humira.
Earnings excluding one-time items of $1.23 a share beat by 1 cent the average of 19 analyst estimates compiled by Bloomberg. Revenue rose 2 percent to $9.8 billion, helped by $2.3 billion in Humira sales, the Abbott Park, Illinois-based company said in a statement today.